October 7, 2026

What PHLEX USA Revealed About the Challenges Launch Teams Share

This past week in Boston, launch leaders from across the pharmaceutical industry gathered for the inaugural US Pharmaceutical Launch Excellence Summit (PHLEX USA). Within3’s CEO Erin Mistry delivered a signature keynote, “‘Too Late’ Is Too Expensive”, and joined the AI in Launch panel alongside leaders from Vera Therapeutics, Biogen, and Vertex Pharmaceuticals.

Across two days of sessions spanning neurology, oncology, and rare disease launches, one thread ran through nearly every conversation: information is scattered across systems and functions, insight arrives too late to act on, and nobody has yet fully worked out how AI fits into a process that relies on evidence, compliance, and human judgment.

Here’s what else surfaced at PHLEX, and what those themes mean for launch teams.

Theme 1: Shared operational challenges

Ask five companies why a launch underperformed, and you’ll likely hear five different stories. However, the root cause is often shared. Launch leaders at PHLEX kept circling back to the idea that information currently moves slower than the market, and that lag is costly.

Erin’s keynote opened with a deceptively simple point: that market share rarely shifts all at once. It moves as access barriers solidify, as competitive narratives gain momentum, and as HCP confidence evolves often months before traditional reporting catches up. By the time any dashboard confirms the shift, the launch isn’t adjusting to the market anymore. In fact it’s already fallen behind.

That lag between when a signal first appears and when a team is able to act on it was the central thesis of the summit. Vera Therapeutics, Takeda, Ionis, Sanofi, and Viridian all have launches in motion as we speak, each shaped by a different kind of assumption: early adoption, regulatory timing, prescriber breadth, label expansion, administration schedules, et cetera. Every one of those assumptions can shift. The real question is how early a team can detect it.

Theme 2: AI needs purpose and accountability 

The AI in Launch panel didn’t bother to pretend that AI has solved pharma’s launch problems. The technology is being used – carefully – and the panel was candid about both its value and its limitations. In Medical Information, teams are using AI to check promotional and medical claims against thousands of references – a process one panelist said used to consume nearly 28 hours out of their week. AI doesn’t replace the reviewer’s judgment; it flags what needs a real look, so the reviewer’s time goes toward the calls that actually require it. In field medical, AI pulls together scattered signals, inquiries, KOL profiling, and sentiment into a single view before and after an HCP interaction – freeing up time for the conversation itself. In Market Access, teams described using AI to iterate on strategy and synthesize market sentiment in hours versus weeks previously.

These are workflow gains not proof of better patient outcomes, and the panel was careful not to conflate the two. People remain responsible for validating the insights that AI surfaces, and for deciding what to do with them. Panelists also raised a quieter risk: bolting disconnected AI tools onto existing systems can reproduce the silos they’re trying to escape. An army of AI agents that don’t talk to each other, or that action things that require a human decision-maker, isn’t progress.

An AI Reckoning, Within3’s recent look at why more AI deployment hasn’t yet equated to more impact, goes deeper on this issue. 

Theme 3: A connected view reveals the barriers launch plans overlook

In Erin’s keynote, she shared a case study of a neurology launch with seemingly everything going for it – strong clinical evidence, solid awareness –  and yet prescribing still came in below expectations. No single function could explain why, because no single function had access to the full picture. Commercial’s view showed strong evidence and awareness, which wasn’t the problem. Medical’s virtual advisory boards surfaced real barriers in patient identification and the prescribing pathway. Field insights added something neither had: clinicians wanted peer validation before writing the first script – they needed to hear from a colleague who had already used the product and seen it in action. Social and claims analysis showed where, and among which networks, those barriers clustered.

No team was mistaken about what it saw, and yet none of them saw the whole bottleneck. Once those individual views came together, the fix wasn’t more evidence or greater awareness. It was messaging and field engagement aimed at the real barriers: patient identification, the prescribing pathway, and peer validation in the specific physician groups that mattered most.

It’s worth calling out a related gap here: ‘eligible’ isn’t the same as ‘ready’. A patient can meet every clinical criterion for a therapy and still not be a near-term candidate to switch; depending on clinical readiness, a patient’s and physician’s willingness to change, coverage and cost, and whether the operational pieces are in place. That gap moves faster than eligibility does, and it’s an early signal worth watching in its own right. That’s only possible, though, if each function’s inputs stay protected: Medical, Commercial, and Market Access combine into one aggregated, compliant view – not a shared raw feed.

Theme 4: Intelligence should change decisions 

The Defining Launch Success panel put a sharper point on something most teams already feel deeply: that speed, access, and impact aren’t interchangeable, and they can’t carry equal weight. Panelists argued that impact, a sustainable model built around patients who are actually identified, engaged, and started on therapy, has to anchor the other two. Access without impact isn’t sustainable, and speed without either is just risk.

That reframes what it means to measure a launch. The real test isn’t whether a team completed its planned activities. It’s what changed because of what the team learned: did stakeholder understanding or intent shift, did behavior or patient pathways change, and critically, how long did it take between a credible signal and a decision? That doesn’t mean reacting to every early number. Panelists cautioned against pivoting off the first dip in a KPI before confirming it’s a signal rather than just noise. A credible warning may call for validation or closer monitoring first – not an immediate overcorrection. The right measures differ by function and by asset. There’s no universal scorecard.

The Pharma Measurement Playbook goes deeper on building the chain of evidence from activity to stakeholder behavior, and finally, to patient impact. 

Three questions to pose your team

Erin Mistry closed her keynote by posing three questions every launch team should be asking right now:

  1. Which launch assumption would hurt most if it proved untrue?
  2. Where would the first credible warning appear?
  3. How quickly could your team validate that warning, and respond?

Getting useful answers depends on seeing the full picture: public signals (publications, congresses, digital sentiment, claims and access data) alongside the private insight already sitting inside your organization (field activity, advisory boards, CRM data, market research). 

Within3 Launch Intelligence™ connects those two layers into one compliant, role-based view, so teams can identify the voices actually shaping the market – not just the usual KOL list – and recognize a shift while it’s still forming rather than after reporting confirms it. None of this replaces judgment – it simply gives teams the time to use it. If PHLEX panellists and attendees made one thing clear, it’s that the companies winning the next wave of launches won’t be the ones running the most activity. They’ll be the ones who see change early enough to act on it.

For more on why AI deployment and launch measurement both need a rethink, read An AI Reckoning and The Pharma Measurement Playbook. 

Related Posts:

EDC clinical trials

Understanding the basics of EDC clinical trials

Why electronic data capture systems are essential tools in clinical trials.
automate data transformation

Automate data transformation for healthcare and pharma

Automating data transformation draws actionable insights quicker to improve patient outcomes and drug development. Read to learn more.

Top Takeaways from Beyond the Buzz: Practical AI for Launch Impact

In our recent webinar with MAPS, a panel of experts discussed how medical affairs teams can use AI for earlier alignment, stronger insight generation, and more confident launch decisions.